Exploratory Analysis of Single-Gene Predictive Biomarkers in HERA DASL Cohort Reveals That C8A mRNA Expression Is Prognostic of Outcome and Predictive of Benefit of Trastuzumab | Zendy

Scooter Willis | Zendy; Varvara Polydoropoulou | Zendy; Yuliang Sun | Zendy; Brandon Young | Zendy; Zoi Tsourti | Zendy; Dimitris Karlis | Zendy; Bradley Long | Zendy; Xiaoqian Lin | Zendy; Stephanie Theel | Zendy; Jennifer Carlson | Zendy; Balázs Győrffy | Zendy; Casey Williams | Zendy; Mark Abramovitz | Zendy; Urania Dafni | Zendy; Mitch Dowsett | Zendy; Brian LeylandJones | Zendy

Open Access

Exploratory Analysis of Single-Gene Predictive Biomarkers in HERA DASL Cohort Reveals That C8A mRNA Expression Is Prognostic of Outcome and Predictive of Benefit of Trastuzumab

Author(s) -

Scooter Willis,

Varvara Polydoropoulou,

Yuliang Sun,

Brandon Young,

Zoi Tsourti,

Dimitris Karlis,

Bradley Long,

Xiaoqian Lin,

Stephanie Theel,

Jennifer Carlson,

Balázs Győrffy,

Casey Williams,

Mark Abramovitz,

Urania Dafni,

Mitch Dowsett,

Brian LeylandJones

Publication year - 2018

Publication title -

jco precision oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.405

H-Index - 22

ISSN - 2473-4284

DOI - 10.1200/po.18.00016

Subject(s) - trastuzumab , cohort , medicine , oncology , outcome (game theory) , gene expression , gene , messenger rna , cancer research , biology , cancer , genetics , breast cancer , mathematics , mathematical economics

The Herceptin Adjuvant study is an international multicenter randomized trial that compared 1 or 2 years of trastuzumab given every 3 weeks with observation in women with human epidermal growth factor 2-positive (HER2+) breast cancer after chemotherapy. Identification of biomarkers predictive of a benefit from trastuzumab will minimize overtreatment and lower health care costs.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research